TOKYO, Jan 5 (Reuters) - Japanese drugmaker Dainippon Sumitomo Pharma (4506.T) said on Tuesday it applied on Dec. 30 for U.S. marketing approval of its key experimental schizophrenia drug, lurasidone.
The Osaka-based company, which sells the hypertension drugs Amlodin and Prorenal, expects to win approval and launch the drug in the world’s largest drug market in 2011, a Dainippon Sumitomo spokesman said.
“We were able to file the application slightly ahead of our target schedule of the first quarter, 2010. Our target to launch the drug in the United States in 2011 remains unchanged,” said the spokesman, Katsuya Kiyose.
Dainippon Sumitomo bought U.S. drugmaker Sepracor Inc SEPR.H last October for $2.6 billion, seeking to capitalise on Sepracor’s sales force of 1,200 familiar with central nervous disorders to maximise the sales of lurasidone. [ID:nT42454] (Reporting by Yumiko Nishitani)